Contract win with US Group Pu

RNS Number : 6741F
Surgical Innovations Group PLC
18 January 2010

Press Release 

18 January 2010

Surgical Innovations Group plc

("SI" or "the Group")

Contract win with leading US Group Purchasing Organisation

for laparoscopic instrumentation

Surgical Innovations Group plc (AIMSUN), the designer and manufacturer of innovative medical devices, is pleased to announce that its US Master Distributor, Surgical Innovations US Inc. ("SI USA"), has signed a three year agreement with one of the largest Group Purchasing Organisations ("GPO") in the US, effective from February 2010.

GPOs help hospitals reduce costs by aggregating volume to negotiate favourable purchasing terms with vendors. The agreement provides an opportunity for SI, through SI USA, to gain access to the GPO's 2,200 member hospitals in the US with its Resposable® laparoscopic instrumentation portfolio, Logi®Range, an ergonomic system which combines reusable handles with disposable scissor blades and graspers This provides surgeons with high quality, but cost effective instruments, for performing laparoscopic surgery. 

Commenting on the agreement, Graham Bowland, Managing Director of Surgical Innovations Limited, said: "This agreement with one of the US's leading GPOs strengthens SI's strategy of developing the Logi®Range brand through our collaboration with SI USA.  The 2,200 member hospitals represent a considerable proportion of all US hospitals, therefore the agreement provides us with significant access to the US laparoscopic instrumentation market, which is estimated to be worth $150 million per annum.  We look forward to seeing substantial sales growth of the Logi®Range as member hospitals are introduced to the brand."

Ends -

  For further information:

Surgical Innovations Group plc

Doug Liversidge, Chairman

Tel: +44 (0) 113 230 7597 

Graham Bowland, Finance Director

Tel: +44 (0) 113 230 7597 

Westhouse Securities Limited

Tim Feather / Matthew Johnson

Tel: +44 (0) 113 246 2611 

Media enquiries:

Abchurch Communications

Sarah Hollins / Simone Elviss

Tel: +44 (0) 20 7398 7728 

Notes to Editors:

About Surgical Innovations Group plc

Surgical Innovations Group plc specialises in the design and manufacture of innovative devices for use in minimally invasive surgery and industrial markets. The Group has two trading subsidiaries Surgical Innovations Limited and Haemocell Limited

The Group employs over 80 people and has its manufacturing facility based in Leeds, covering 32,000 square feet, which enables the in-house design and manufacture of its own products to the highest quality standards. Surgical Innovations, through an established network of 40 distribution partners, sells in all of the major medical markets including North America, Europe, South Africa, the Middle East, South-East Asia and Australia

Surgical Innovations Limited, which is the main division of the Group, is focused on developing medical instruments for the laparoscopic surgery market, minimally invasive surgery of the abdomen. The Group has pioneered the resposable™ concept, which combines both single use and reusable components which ensures an ongoing revenue stream and delivers the optimum procedure performance to cost ratio. The Groups products include:

YelloPort plus

a resposable™ laparoscopic port access system that combines both single-use and reusable components


laparoscopic instrument system using Resposable® technology to deliver the cost effectiveness of a reusable instrument with the optimum performance of a disposable.

Quick Range

single-use instruments, with an ergonomic handle to ensure accurate control of the instrument. The range includes scissors, graspers and dissectors 

In addition to its own branded instruments, the Group also designs and manufactures devices on a private label basis for large medical device companies including Teleflex Medical, Gyrus, Olympus and Cardinal Health

Haemocell Limited specialises in equipment for Autologous Blood Transfusion, which is the collection and re-infusion of a patient's own blood either during or after surgery, eliminating the widely-documented risks of infection from donated blood

For more information, see

This information is provided by RNS
The company news service from the London Stock Exchange
UK 100

Latest directors dealings